Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
IMVT Immunovant
4.605
+0.085+1.88%
YOY
Do not show
Hide blank lines
(Q1)2022/06/30(FY)2022/03/31(Q4)2022/03/31(Q3)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
35.1% 40.38M 44.32% 156.03M 63.32% 47.23M 30.44% 41.27M
Selling and administrative expenses
6.84% 11.95M 37.23% 54.23M 47.94% 15.24M 9.16% 11.52M
-General and administrative expense
6.84% 11.95M 37.23% 54.23M 47.94% 15.24M 9.16% 11.52M
Research and development costs
51.99% 28.43M 48.4% 101.81M 71.83% 31.99M 41.08% 29.76M
Operating profit
-35.1% -40.38M -44.32% -156.03M -63.32% -47.23M -30.44% -41.27M
Net non-operating interest income expense
Other net income (expense)
156.55% 354K -338.11% -781K -93.53% 44K 77.34% -114K
Other non- operating income (expenses)
156.55% 354K -338.11% -781K -93.53% 44K 77.34% -114K
Income before tax
-31.16% -40.02M -45.48% -156.81M -67.1% -47.18M -28.75% -41.39M
Income tax
958.54% 352K 76.54% -84K 84.81% -12K 0
Net income
-32.5% -40.37M -45.89% -156.73M -67.52% -47.17M -30.24% -41.39M
Net income continuous Operations
-32.5% -40.37M -45.89% -156.73M -67.52% -47.17M -30.24% -41.39M
Minority interest income
Net income attributable to the parent company
-32.5% -40.37M -45.89% -156.73M -67.52% -47.17M -30.24% -41.39M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-32.5% -40.37M -45.89% -156.73M -67.52% -47.17M -30.24% -41.39M
Basic earnings per share
-12.9% -0.35 -17.21% -1.43 -46.43% -0.41 -12.5% -0.36
Diluted earnings per share
-12.9% -0.35 -17.21% -1.43 -46.43% -0.41 -12.5% -0.36
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
CEO: Dr. Peter Salzmann, M.B.A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...